6 juni 2023: ASCO 2023

In de week van 2 t/m 6 juni was er weer ASCO 2023. Hier een aantal aanbevolen abstracten gerelateerd aan spijsverteringskanker waaronder vormen van darmkanker en maagkanker door vooraanstaande artsen en oncologen wereldwijd.

Klik op de nummers van de abstracten om deze te lezen of te downloaden:

Aanbevolen door Dr. Elizabeth Smyth, Consultant Medical Oncologist bij Oxford University Hospitals NHS Foundation Trust en lid van de Advisory Board of PracticeUpdate Oncology:

Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

4000 ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. M Terashima, Y-K Kang, YW Kim, et al

Take-Home Message

  • The results of an immune checkpoint inhibitor (nivolumab) in combination with adjuvant chemotherapy in the treatment of pathological stage III gastric or gastroesophageal junction (G/GEJ) cancer are reported. The study was conducted in Japan, China, Korea, and Taiwan. Participants had undergone D2 or more extensive gastrectomy and were randomized to nivolumab/chemotherapy or to placebo/chemotherapy.
  • The study did not meet its primary efficacy endpoint of centrally assessed relapse-free survival, with 3-year relapse-free rates of 68.4% in the nivolumab arm and 65.3% in the placebo arm. Grade≥3 treatment-associated adverse events were 54.4% in the nivolumab arm and 46.8% in the placebo arm.

4100 Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. S Yuan, R-C Nie, Y Jin, et al

Take-Home Message

  • This prospective randomized phase II trial was designed to evaluate the effectiveness of adding the PD-1 antibody toripalimab to perioperative chemotherapy in patients with locally advanced resectable gastric or GEJ cancer. In total, 108 participants were enrolled and assessed using an intention-to-treat analysis. The toripalimab plus chemotherapy arm achieved a higher proportion of pathological complete regression/moderate regression rate (the primary endpoint) compared with the chemotherapy alone arm. The pathological response rate was higher (24.1%) in the toripalimab arm than in the chemotherapy arm (9.3%). Rates of surgical morbidity and mortality were comparable between the arms, as were rates of treatment-related adverse events.
  • The results suggest that perioperative toripalimab plus chemotherapy may be an option for patients with locally advanced resectable gastric or GEJ cancer.

Monday, June 5, 2023; 11:30 AM–1:00 PM CDT
Poster Discussion Session
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

4014 KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. SY Rha, L Wyrwicz, PEY Weber, et al

4027 A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). SJ Klempner, BB Sonbol, ZA Wainberg, et al

Plaats een reactie ...

Reageer op "ASCO 2023: aanbevolen abstracten gerelateerd aan spijsverteringskanker waaronder vormen van darmkanker en maagkanker door vooraanstaande medisch specialisten"

Gerelateerde artikelen

Gerelateerde artikelen

ASCO 2023: aanbevolen abstracten >> ASCO 2020: aanbevolen abstracten >> Aanbevolen abstracten voor >> ASCO 2024: aanbevolen abstracten >>